Author:
Belova A. N.,Rasteryaeva M. V.,Zhulina N. I.,Belova E. M.,Boiko A. N.
Publisher
Springer Science and Business Media LLC
Reference124 articles.
1. J. Havla, I. Kleiter, and T. Kumpfel, “Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?” Ther. Clin. Risk Manag., 9, 361–369 (2013), doi:
https://doi.org/10.2147/TCRM.S41552.
2. J. Honce, L. Nagae, and E. Nyberg, “Neuroimaging of natalizumab complications in multiple sclerosis: PML and other associated entities,” Mult. Scler. Int., 809252 (2015), publ. online Sept. 21, 2015, doi:
https://doi.org/10.1155/2015/809252
.
3. N. V. Matievska, “Inflammatory immune reconstitution syndrome in HIV-infected patients: risk factors, clinical manifestations, outcomes, and prophylaxis,” Vestn. Balt. Fed. Univ. im. Kanta, No. 7, 44–51 (2012).
4. S. A. Shelburne, F. Visnegarwalaa, J. Darcourtc, et al., “Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy,” AIDS, 19, No. 4, 399–406 (2005).
5. G. Breton, X. Duval, C. Estellat, et al., “Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy,” Clin. Infect. Dis., 39, 1709–1712 (2004).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Fingolimod withdrawal;Reactions Weekly;2018-08